Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12264763 | 0.76 | KDM4E (0.42) | ALDH1A1KDM4E | |
| SCHEMBL11778334 | 0.73 | CYP11B2 (0.54) | ALDH1A1CYP11B2CYP11B1OPRK1PDE4D | |
| SCHEMBL21061364 | 0.70 | CYP11B2 (0.45) | ALDH1A1CYP11B2NOTUMCYP11B1DRD4 | |
| SCHEMBL313900 | 0.68 | HPGD (0.48) | ALDH1A1CYP11B2CYP11B1HPGD | |
| SCHEMBL9851802 | 0.67 | CYP11B2 (0.41) | ALDH1A1CYP11B2NOTUMCYP11B1OPRK1 | |
| SCHEMBL24167142 | 0.65 | GSK3B (0.44) | ALDH1A1GSK3BNOTUMHPGDNPSR1 | |
| SCHEMBL28369593 | 0.65 | CYP11B2 (0.40) | CYP11B2CYP11B1DRD4OPRK1PDE4D | |
| SCHEMBL9391482 | 0.63 | BRPF1 (0.41) | ALDH1A1CYP11B2CYP11B1OPRK1PDE4D | |
| SCHEMBL29821241 | 0.63 | BRPF1 (0.41) | ALDH1A1CYP11B2CYP11B1OPRK1PDE4D | |
| SCHEMBL8145288 | 0.63 | GRM5 (0.43) | ALDH1A1GSK3BOPRK1PDE4DHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| EP-1966211-A1 | TRIAZOLE DERIVATIVES | Merck Patent GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079820-A1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306042-A1 | Triazole Derivatives | TGFBR1, TGFBR2, SMAD3 | ALDH1A1 2295/4885GSK3B 73/4885CYP11B2 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.